Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study

JCO Precis Oncol. 2022 Mar:6:e2100286. doi: 10.1200/PO.21.00286.

Authors

Affiliations

¹ Mary Bridge Children's Hospital, Division of Pediatric Hematology/Oncology, Tacoma, WA.
² Papé Pediatric Research Institute, Division of Pediatric Neurology, Department of Pediatrics, Oregon Health and Sciences University, Portland, OR.
³ Hospital for Sick Children and University of Toronto, Toronto, CA.
⁴ Section of Pediatric Hematology-Oncology, Department of Pediatrics, Wake Forest School of Medicine, Winston Salem, NC.
⁵ Royal Adelaide Hospital, Adelaide, Australia.
⁶ Women's and Children's Hospital, North Adelaide, Australia.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immune Checkpoint Inhibitors* / pharmacology
Immunotherapy
Neoplasms* / drug therapy

Substances

Immune Checkpoint Inhibitors

Associated data

ClinicalTrials.gov/NCT02992964